"Dyslipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Descriptor ID |
D050171
|
| MeSH Number(s) |
C18.452.584.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dyslipidemias".
Below are MeSH descriptors whose meaning is more specific than "Dyslipidemias".
This graph shows the total number of publications written about "Dyslipidemias" by people in this website by year, and whether "Dyslipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 2 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 3 | 5 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 9 | 2 | 11 |
| 2020 | 4 | 2 | 6 |
| 2021 | 3 | 2 | 5 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dyslipidemias" by people in Profiles.
-
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct; 28(10):923-1049.
-
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
-
Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. J Cardiovasc Pharmacol. 2021 11 01; 78(5):e631-e640.
-
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
-
Risk Factor Characterization of Ischemic Stroke Subtypes Among West Africans. Stroke. 2022 01; 53(1):134-144.
-
Role of dyslipidemia in ischemic stroke patients treated in the telestroke network. Adv Med Sci. 2021 Sep; 66(2):254-261.
-
Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021 01 11; 11(1):430.
-
GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice. Am J Physiol Endocrinol Metab. 2021 01 01; 320(1):E30-E42.
-
Joint effect of race/ethnicity or location of residence and sex on low density lipoprotein-cholesterol among veterans with type 2 diabetes: a 10-year retrospective cohort study. BMC Cardiovasc Disord. 2020 10 15; 20(1):449.
-
Association Between Residential Greenness, Cardiometabolic Disorders, and Cardiovascular Disease Among Adults in China. JAMA Netw Open. 2020 09 01; 3(9):e2017507.